Table_1.xls (13.5 kB)

Irinotecan-treated cancer patients with SNP information, genetic factor, and clinical parameters for incidence of diarrhea.

dataset

posted on 2014-08-15, 03:01 authored by Hiro Takahashi, Kimie Sai, Yoshiro Saito, Nahoko Kaniwa, Yasuhiro Matsumura, Tetsuya Hamaguchi, Yasuhiro Shimada, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi, Haruhiro Okuda, Risa Ichinohe, Anna Takahashi, Ayano Doi, Yoko Odaka, Misuzu Okuyama, Nagahiro Saijo, Jun-ichi Sawada, Hiromi Sakamoto, Teruhiko Yoshida

“UGT1A1*6 or *28” is a genetic factor constructed from 2 polymorphisms (UGT1A1*6 and *28); “2” indicates *6/*6, *28/*28 or *6/*28, “1” indicates *6 or *28, and “0” indicates “other than 2 and 1.” Area: body surface area (m²), PS: performance status, Cr: grade of creatinine, Hg: grade of hemoglobin, Alb: grade of albumin, ALP: grade of alkaline phosphatase, and GOT: grade of glutamic oxaloacetic transaminase. Each laboratory test value (Alb, Hg, GOT, ALP, and Cr) was recorded before the irinotecan therapy. For each type of clinical tests the grade and aberrant values were defined according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC, Version 2.0). C_max/dose: SN38 C_max/dose [10⁻³×m²/L]. AUC: area under the concentration-time curve. AUC ratio: Ratio of AUC_SN38/AUC_CPT-11. 5-FU: 5-fluorouracil, CDDP: cisplatin, MMC: mitomycin C, VP16: etoposide. * and † indicate p<0.05 and 0.05≤p<0.10, respectively. For each concomitant drug, 0 means “not administered,” 1 indicates administered.